Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement.
Am J Clin Nutr
Prasad GV, Wong T, Meliton G, et al. Rhabdomyolysis due to red yeast rice (
) in a renal transplant recipient.
Smith DJ, Olive KE. Chinese red rice-induced myopathy.
South Med J
Liu BH, Wu TS, Su MC, et al. Evaluation of citrinin occurrence and cytotoxicity in
J Agric Food Chem
Silver MA, Langsjoen PH, Szabo S, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction.
Am J Cardiol
Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications.
Yang HT, Lin SH, Huang SY, et al. Acute administration of red yeast rice (
) depletes tissue coenzyme Q(10) levels in ICR mice.
Br J Nutr
Lin CC, Li TC, Lai MM, et al. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia.
Eur J Endocrinol.
Du BM, Lu ZL, Chen Z, et al. The beneficial effects of lipid-lowering therapy with Xuezhikang on cardiac events and total mortality in coronary heart disease patients with or without hypertension: a random, double-blinded, placebo controlled clinical trial.
Zhonghua Xin Xue Guan Bing Za Zhi
Huang CF, Li TC, Lin CC, et al. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients.
Eur J Cardiovasc Prev Rehabil.
Andren L, Andreasson A, Eggertsen R. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.
Eur J Clin Pharmacol.
2007 Aug 15. [Epub ahead of print]
Liu J, Zhang J, Shi Y, et al. Chinese red yeast rice (
) for primary hyperlipidemia: a meta-analysis of randomized controlled trials.
Zhao SP, Lu ZL, Du BM, et al. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS).
J Cardiovasc Pharmacol.
Ye P, Lu ZL, Du BM, et al. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.
J Am Geriatr Soc.
Lu Z, Kou W, Du B, et al. Effect of xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.
Am J Cardiol.
FDA warns consumers to avoid red yeast rice products promoted on internet as treatments for high cholesterol products found to contain unauthorized drug. US Food and Drug Administration website. Available at:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108962.htm. Published August 9, 2007. Accessed October 3, 2011.
Red yeast rice. US Food and Drug Administration website. Available at:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm153116.htm. Published August 9, 2007. Accessed October 3, 2011.
Liu ZL, Liu JP, Zhang AL, et al. Chinese herbal medicines for hypercholesterolemia.
Cochrane Database Syst Rev.
Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain—a systematic review and meta-analysis. Atherosclerosis. 2015;240(2):415-423.